GlassScriptPhysician profile
Emily A Ostrowski
NPI 1043212483
$5,198.63
in general payments reported to CMS, 2019-2025
34 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $903 · 2021: $803 · 2022: $340 · 2023: $547 · 2024: $909 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,173.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,006.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $481.35 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $455.48 | 2021-2025 | |
| Exact Sciences Corporation | $287.87 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $285.70 | 2021-2025 | |
| Dynavax Technologies Corporation | $156.53 | 2023-2025 | Heplisav-B |
| Amgen INC. | $140.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.13 | 2019-2024 | Jardiance |
| Eisai INC. | $134.32 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.06 | 2021-2022 | |
| Ibsa Pharma INC. | $76.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $71.16 | 2019-2023 | Arexvy, Shingrix |
| Phadia US INC. | $68.70 | 2019-2021 | |
| Amarin Pharma, INC. | $62.41 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.29 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $42.65 | 2025 | |
| Idorsia Pharmaceuticals US INC | $39.79 | 2023 | Quviviq |
| Astellas Pharma US INC | $34.29 | 2020 | |
| Nevro Corp. | $31.94 | 2019 | |
| Si-Bone, INC. | $31.34 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.45 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.68 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $23.19 | 2019 | |
| Shield Therapeutics INC | $22.02 | 2024 | |
| Nestle Healthcare Nutrition INC. | $21.14 | 2022 | |
| Abbott Laboratories | $20.04 | 2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $19.36 | 2019 | |
| Lucid Diagnostics INC. | $18.01 | 2023 | |
| Angiodynamics, INC. | $17.79 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.42 | 2020 | |
| Painteq LLC | $14.41 | 2023 | Painteq |
| Genentech USA, INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.